An international observational program has shown that Ergoferon is effective in the treatment of ARVIs and influenza at early and later stages
Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2017!
Start-up meeting associated with initiation of clinical studies of Ergoferon
Four extensive multicenter randomized trials have been completed which evaluated the safety and efficacy of two release-active drugs – liquid Ergoferon and Rengalin – in children and adults with acute respiratory infections (ARIs).
Laboratory of Influenza under Pasteur Institute and APcis carried out a study in cooperation with Materia Medica Holding.
Opening Research Laboratory - breakthrough in comprehensive studies and manufacturing developments
MATERIA MEDICA HOLDING NAMED 2017 BEST EMPLOYER!
Conference Report: International Scientific and Practical Conference –“The Older Patient. Quality of Life”
The18th All-Russian Scientific and Practical Neurology Conference with Foreign Guest Speakers – “DAVIDENKOV READINGS 2017”
Dear Colleagues! Data on the Company’s Products were announced at European Respiratory Society International Congress in Milan, September 9-13.
Highlights from Symposium on Cellular and Molecular Mechanisms of Movement Disorders held at the 4th National Congress with Foreign Guest Speakers on Parkinson's Disease and Movement Disorders
Report from Symposium on Medical Comorbidities in Elderly Patients held at the 9th International Congress “Neurorehabilitation 2017”
Released Activity (Contemporary View of Homeopathy and Non-homeopathy)
Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2016!
Officials of Mexico National Institute of Pediatrics confirmed recommendations on Anaferon for children application for prevention and treatment of acute infectious respiratory diseases
Materia Medica expands manufacturing unit
3rd Drug Discovery & Therapy World Congress
First Russian GMP certificate
7 International Congress of Antibodies